Literature DB >> 24891323

B-cell prolymphocytic leukemia: a specific subgroup of mantle cell lymphoma.

Vincent H J van der Velden1, Patricia G Hoogeveen1, Dick de Ridder2, Magdalena Schindler-van der Struijk1, Menno C van Zelm1, Mathijs Sanders3, Dennis Karsch4, H Berna Beverloo5, King Lam6, Alberto Orfao7, Pieternella J Lugtenburg3, Sebastian Böttcher4, Jacques J M van Dongen1, Anton W Langerak1, Mies Kappers-Klunne3, Kirsten van Lom3.   

Abstract

B-cell prolymphocytic leukemia (B-PLL) is a rare mature B-cell malignancy that may be hard to distinguish from mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL). B-PLL cases with a t(11;14) were redefined as MCL in the World Health Organization 2008 classification. We evaluated 13 B-PLL patients [7 being t(11;14)-positive (B-PLL+) and 6 negative (B-PLL-)] and compared them with MCL and CLL patients. EuroFlow-based immunophenotyping showed significant overlap between B-PLL+ and B-PLL-, as well as between B-PLL and MCL, whereas CLL clustered separately. Immunogenotyping showed specific IGHV gene usage partly resembling MCL. Gene expression profiling showed no separation between B-PLL+ and B-PLL- but identified 3 subgroups. One B-PLL subgroup clustered close to CLL and another subgroup clustered with leukemic MCL; both were associated with prolonged survival. A third subgroup clustered close to nodal MCL and was associated with short survival. Gene expression profiles of both B-PLL+ and B-PLL- showed best resemblance with normal immunoglobulin M-only B-cells. Our data confirm that B-PLL+ is highly comparable to MCL, indicate that B-PLL- also may be considered as a specific subgroup of MCL, and suggest that B-PLL is part of a spectrum, ranging from CLL-like B-PLL, to leukemic MCL-like B-PLL, to nodal MCL-like B-PLL.
© 2014 by The American Society of Hematology.

Entities:  

Mesh:

Year:  2014        PMID: 24891323     DOI: 10.1182/blood-2013-10-533869

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  6 in total

Review 1.  How to Choose the Best Treatment and Testing for Chronic Lymphocytic Leukemia in the Tsunami of New Treatment Options.

Authors:  Cecilia C S Yeung; Mazyar Shadman
Journal:  Curr Oncol Rep       Date:  2019-07-20       Impact factor: 5.075

Review 2.  Prolymphocytic Leukemia: New Insights in Diagnosis and in Treatment.

Authors:  Aude Collignon; Anne Wanquet; Elsa Maitre; Edouard Cornet; Xavier Troussard; Thérèse Aurran-Schleinitz
Journal:  Curr Oncol Rep       Date:  2017-04       Impact factor: 5.075

3.  A high mutation rate of immunoglobulin heavy chain variable region gene associates with a poor survival and chemotherapy response of mantle cell lymphoma patients.

Authors:  Xianqian Li; Ning Wu; Bin Li
Journal:  Medicine (Baltimore)       Date:  2019-05       Impact factor: 1.817

4.  De novo chronic lymphocytic leukemia/prolymphocytic leukemia or B-cell prolymphocytic leukemia? The importance of integrating clinico-morphological and immunophenotypic findings in distinguishing chronic lymphoproliferative diseases with circulating phase.

Authors:  Zachariah Chowdhury; Yookarin Khonglah; Susmita Sarma; Pranjal Kalita
Journal:  Autops Case Rep       Date:  2020-12-08

Review 5.  Progress in molecular feature of smoldering mantle cell lymphoma.

Authors:  Panruo Jiang; Aakash Desai; Haige Ye
Journal:  Exp Hematol Oncol       Date:  2021-07-13

6.  [The consensus for differential diagnosis of B cell chronic lymphoproliferative diseases in China (2018 edition)].

Authors: 
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2018-05-14
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.